Abstract
Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/s2213-8587(23)00355-8
Copy DOIJournal: The lancet. Diabetes & endocrinology | Publication Date: Dec 4, 2023 |
Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR
Join us for a 30 min session where you can share your feedback and ask us any queries you have